<DOC>
	<DOCNO>NCT00183976</DOCNO>
	<brief_summary>This study patient treat either treatment work lymphoma come back .</brief_summary>
	<brief_title>Pegylated Liposomal Doxorubicin ( Doxil ) With Rituximab Relapsed AIDS-Related Non-Hodgkin 's Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Primary Effusion</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histologically cytologically document Bcell nonHodgkin 's lymphoma [ NHL ] ( diffuse mixed , diffuse follicular large Bcell , immunoblastic ) , Burkitt Burkittlike lymphoma , primary effusion lymphoma . Seropositive HIV approve test ( prior documentation HIV seropositivity acceptable ) . Failed relapse least 1 prior chemotherapy treatment ( chemotx ) regimen could 2 prior chemotx regimens one anthracyclinecontaining regimen . Prior treatment ( tx ) rituximab allow . All stage disease Measurable evaluable tumor Greater equal 18 year age Karnofsky performance status great 50 % Absolute granulocyte count ( AGC ) great 1.0 ; platelet great 75,000 ; hemoglobin ( Hgb ) great 8.0 ( unless parameter abnormal secondary lymphomatous involvement marrow , due HIVrelated thrombocytopenia ) . Bilirubin le 2.0 ( unless elevate secondary lymphomatous involvement liver biliary system due HIVrelated medication Crixivan ) . Creatinine le 2.5 creatinine clearance great 60 ml/min Multigated acquisition ( MUGA ) scan 2D echocardiogram indicating leave ventricular ejection fraction ( LVEF ) great equal 50 % within 42 day prior first dose study drug . Patients central nervous system ( CNS ) involvement eligible provide systemic lymphomatous disease also present . Concurrent therapy HIV license agent agent available expanded access program require . Signed informed consent include Health Insurance Portability Accountability Act 1996 ( HIPAA ) authorization . Acute intercurrent infection may interfere plan protocol . Patients mycobacterium avium exclude . Chronic therapy potentially myelosuppressive agent allow provided entry hematologic criterion meet . Second active tumor . Patients nonmelanomatous skin cancer , insitu cervical cancer , Kaposi 's sarcoma , require systemic chemotherapy may enter study . Primary CNS lymphoma . Documented history congestive heart failure ( CHF ) , hemodynamically unstable arrhythmia , myocardial infarction ( MI ) precede 6 month , evidence electrocardiogram ( EKG ) untreated cardiac ischemia . Prior exposure liposomal anthracycline ( liposomal doxorubicin daunorubicin ) treatment lymphoma . Prior exposure conventional doxorubicin allow . Prior radiation therapy within 4 week , unless emergency condition secondary lymphoma ( i.e. , CNS tumor , cord compression ) Prior systemic chemotherapy biologic therapy within 3 week History hypersensitivity reaction anthracyclines granulocyte colonystimulating factor ( GCSF ) History hypersensitivity reaction attribute conventional formulation doxorubicin hydrochloride ( HCl ) Investigational agent ( ) within 4 week start study therapy . History cardiac disease New York Heart Association ( NYHA ) great equal Class II , clinical evidence CHF Pregnant nursing mother .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Diffuse mix NHL</keyword>
	<keyword>Diffuse follicular large B-cell NHL</keyword>
	<keyword>Immunoblastic NHL</keyword>
	<keyword>Burkitt Burkitt-like lymphoma</keyword>
</DOC>